Southern Acids (malaysia) Bhd. · MYX:SAB
Southern Acids (malaysia) Bhd — Southern Acids (M) Berhad — Shareholder Meeting (August 2023)
15 slides from Southern Acids (malaysia) Bhd's shareholder meeting presentation, Aug 30, 2023
Slide 1: Southern Acids (M) Berhad 42nd Annual General Meeting
SOUTHERN ACIDS (M) BERHAD 42nd ANNUAL GENERAL MEETING 30 AUGUST 2023 SHAREHOLDERS BRIEFING
Slide 2: Source of Information & Disclaimer
SLIDE 1 SOURCE OF INFORMATION & DISCLAIMER Source of Information Used For The Presentation The Company’s 2023 Annual Report; and All other information that are available from Bursa Malaysia Securities Berhad’s website. Disclaimer Information contained in this presentation is intended solely for
Slide 3: Content
SLIDE 2 CONTENT 1. Southern Acids (M) Berhad (“SAB or the Company”) & Its Subsidiaries a. SAB & Its Subsidiaries’ Key Financial Highlights For The Financial Year Ended 31 March 2023 (“FY2023”); and b. SAB & Its Subsidiaries’ Financial Performance For The FY2023 2. The Respective Segments a. Review O
Slide 4: SAB & Its Subsidiaries Key Financial Performance & Highlights for FY2023
SOUTHERN ACIDS (M) BERHAD SAB & ITS SUBSIDIARIES KEY FINANCIAL PERFORMANCE & HIGHLIGHTS FOR FY2023
Slide 5: SAB & Its Subsidiaries' Financial Performance
SLIDE 3 SAB & ITS SUBSIDIARIES’ FINANCIAL PERFORMANCE FY2023 FY2022 Changes RM’000 RM’000 RM’000 Consolidated Revenue 1,099,875 1,176,249 (76,374) Consolidated Profit Before Tax 74,909 149,855 (74,946) (“PBT”) /(Loss Before Tax)(“LBT”) Segment’s PBT/(LBT) Oleochemical Manufacturing (27,149) 43,763 (
Slide 6: SAB & Its Subsidiaries' Key Financial Highlights
SLIDE 4 SAB & ITS SUBSIDIARIES’ KEY FINANCIAL HIGHLIGHTS FY2023 FY2022 Changes (RM’000) (RM’000) (RM’000) Consolidated Revenue 1,099,875 1,176,249 (76,374) Consolidated Profit After Tax And 33,292 94,420 (61,128) Minority Interest Earnings Per Share 24.3 sen 69.0 sen (44.7 sen) Net Asset Per Share 5
Slide 7: Review of the Respective Segments' Financial Performance
SOUTHERN ACIDS (M) BERHAD REVIEW OF THE RESPECTIVE SEGMENTS’ FINANCIAL PERFORMANCE
Slide 8: Oleochemical Manufacturing Financial Performance
SLIDE 5 OLEOCHEMICAL MANUFACTURING FINANCIAL PERFORMANCE FY2023 FY2022 Changes RM’000 RM’000 RM’000 Revenue 478,996 494,334 (15,338) PBT/(LBT) Core PBT/(LBT) (27,777) 33,317 (61,094) Non-Core PBT 628 10,446 (9,818) (27,149) 43,763 (70,912) Highlights • A marginal drop in revenue but a substantial LB
Slide 9: Oleochemical Manufacturing Outlook for FY2024
SLIDE 6 OLEOCHEMICAL MANUFACTURING OUTLOOK FOR FY2024 Challenging, key factors are as follows:- 1. External factors; Highly competition in global market; USD/MYR exchange rate; and Volatility of commodity prices. 1. Internal factors; Rising production costs; and Increasing trend of regulat
Slide 10: Milling & Cultivation Financial Performance
SLIDE 7 MILLING & CULTIVATION FINANCIAL PERFORMANCE FY2023 FY2022 Changes RM’000 RM’000 RM’000 Revenue 484,796 568,484 (83,688) PBT Core PBT 52,417 71,510 (19,093) Non-Core PBT 22,135 15,142 6,993 74,552 86,652 (12,100) Highlights 1. Lower revenue was mainly due to lower average selling price (“ASP”
Slide 11: Milling & Cultivation Outlook for FY2024
SLIDE 8 MILLING & CULTIVATION OUTLOOK FOR FY2024 Challenging, the performance of Milling & Cultivation is largely subjected to the following uncontrollable factors:- Commodity prices; Availability of fresh fruit bunches, externally and internally; Higher production costs such as labour, fertil
Slide 12: Healthcare Services Financial Performance
SLIDE 9 HEALTHCARE SERVICES FINANCIAL PERFORMAMCE FY2023 FY2022 Changes RM’000 RM’000 RM’000 Revenue 112,727 95,998 16,729 PBT Core PBT 28,808 23,251 5,557 Non-Core PBT 2,612 3,217 (605) 31,420 26,468 4,952 Highlights 1. Higher revenue was mainly contributed to the increase in number of inpatients;
Slide 13: Healthcare Services Outlook for FY2024
SLIDE 10 HEALTHCARE SERVICES OUTLOOK FOR FY2024 Continue stable growth Continue to improve our service levels as follow:- o High quality of healthcare services o Upgrade of medical facilities; and o Attract pool of medical professionals
Slide 14: SAB & Its Subsidiaries' Outlook for FY2024
SLIDE 11 SAB & ITS SUBSIDIARIES’ OUTLOOK FOR FY2024 In short, we remain cautious, the concern over a weaker than expected economic growth, both locally and globally.
Slide 15: Thank You - Questions & Answers
SOUTHERN ACIDS (M) BERHAD THANK YOU QUESTIONS & ANSWERS
Southern Acids (M) Berhad — Shareholder Meeting (August 2023) on 6ix